A Preclinical PK/PD Mouse Model of LPS-induced Inflammation Permits Targeting of Inflammatory Pathways

Inflammation models emulate key pathological features of human diseases, providing a comprehensive platform for advancing preclinical drug development. The imperative to enhance therapeutic options and address current therapy limitations necessitates the innovation of new anti-inflammatory drugs. Successful drug development relies on robust preclinical frameworks, making the LPS-induced rodent model of inflammation a primary choice. In this study, we targeted the TLR4, RIPK1, and NLRP3 pathways using specific antagonists within the established LPS-induced mouse model, comparing their efficacy with dexamethasone, a widely used anti-inflammatory and immunosuppressive medication.